| BPD-MA | benzoporphyrin derivative monoacid ring a |
| Ce6 | Chlorin e6 |
| DMARDs | disease-modifying antirheumatic drugs |
| FCA | Freund’s complete adjuvant |
| FDA | food and drug administration |
| FLS | fibroblast-like synoviocytes |
| ICG | indocyanine green |
| IL-17 | interleukin-17 |
| IR | infrared |
| LiD | light dose |
| LD50 | 50% of cell mortality after light activation |
| LED | light-emitting diode |
| lpr | lymphoproliferation |
| MRL | Murphy Roths Large |
| m-THPC | meso-tetra(hydroxyphenyl)chlorin |
| MTT | 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide |
| NA | not applicable |
| ND | not determined |
| NIR | near infrared |
| NZW | New Zealand white |
| PDT | photodynamic therapy |
| PEG | polyethylene glycol |
| PFP | perfluoro-n-pentane |
| PLGA | poly(DL-lactide-co-glycolic acid) |
| PpIX | protoporphyrin IX |
| PS | photosensitizer |
| RA | rheumatoid arthritis |
| ROS | radical oxygen species |
| SAA | serum amyloid A |
| SCID | severe combined immunodeficiency |
| TNF | tumor necrosis factor |
| THPC | tetra(hydroxyphenyl)chlorin |
| TPCC | tetra(4-carboxyphenyl)chlorin |
| TPPS2a | meso-tetraphenylporphyrin disulfonate with two sulfonate groups on adjacent phenyl rings |
| TSPP | tetra(4-sulfonatophenyl)porphine |
| WBI | whole body irradiation |